After numerous failures to make immunotherapy effective in microsatellite-stable (MSS) metastatic colorectal cancer, the STELLAR-303 trial shows a statistically significant survival benefit for zenzalintinib plus atezolizumab over regorafenib. This marks a potential breakthrough, offering a new IO-based option for this large patient population.

The STELLAR-303 trial is the first to show an immunotherapy-based regimen provides an overall survival benefit in microsatellite-stable CRC. Crucially, this benefit extends to patients with liver metastases, a subgroup that has historically shown profound resistance to immunotherapy, highlighting the drug's novel mechanism.

A critical reason patients stop ADC treatments is the burden of side effects like skin toxicity or GI issues, not just disease progression. This underscores the urgent need to develop ADCs with better safety profiles, enabling patients to stay on effective therapy longer.

The enzalutamide arms saw discontinuation rates of 20-25% due to adverse events. This high rate reflects a different risk calculation for patients who feel healthy and are asymptomatic. Unlike in advanced disease where patients tolerate more toxicity, this population has a very low threshold for side effects, making early intervention a significant trade-off.

While the STELR-303 trial of zanzalidinib plus atezolizumab in MSS colorectal cancer was technically positive, showing a 1.5-month median overall survival benefit, experts are not enthusiastic. They view the magnitude of benefit as slight and are concerned about increased toxicity, questioning its clinical meaningfulness and potential adoption into practice.

Contrary to the assumption that two drugs are always more toxic than one, the Lenvatinib-Belzutifan combination in the LightSpark-011 trial presented a different, but not quantifiably worse, toxicity profile compared to cabozantinib monotherapy, challenging conventional thinking on combination therapy side effects.

In late-stage metastatic colorectal cancer, the goal shifts from achieving significant tumor shrinkage to stabilizing the disease. This recalibration of 'success' focuses on maintaining quality of life and managing symptoms for patients who have undergone multiple prior therapies.

In the LEAP-010 trial, the combination arm's higher efficacy was offset by significantly greater toxicity (67% vs 38% severe adverse events). This increased treatment burden likely limited sustained therapy and prevented patients from receiving subsequent treatments, ultimately nullifying any survival benefit from improved tumor response.

The STELLAR-303 trial is the first Phase III study to show a significant overall survival benefit for an immunotherapy-based combination (zanzalintinib + atezolizumab) in refractory microsatellite stable (MSS) metastatic colorectal cancer. This validates the IO+TKI approach in a notoriously "cold" tumor type where prior IO trials failed.